Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Long-Term Deferred Tax came in at $113.8 million in Q2 2026, up 9.03% YoY from $104.4 million in Q2 2025, and down 2.71% on a QoQ basis from $117.0 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 8 years of Long-Term Deferred Tax data on file, last reported at $113.8 million in Q2 2026.
- Quarterly Long-Term Deferred Tax rose 9.03% year-over-year to $113.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $113.8 million (up 9.03% YoY) and the FY2025 annual result came in at $126.0 million, up 7.8% from the prior year.
- Long-Term Deferred Tax eased to $113.8 million in Q2 2026, from $117.0 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $126.0 million in Q4 2025 to a low of $10.1 million in Q4 2023.
- A 4-year average of $99.2 million and a median of $110.5 million in 2025 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2024 — Long-Term Deferred Tax jumped 1056.94% — and 2025, when it grew 7.8%.
- Tracing ALNY's Long-Term Deferred Tax over 4 years: stood at $10.1 million in 2023, then jumped by 1056.94% to $116.9 million in 2024, then rose by 7.8% to $126.0 million in 2025, then decreased by 9.67% to $113.8 million in 2026.
- The last three Long-Term Deferred Tax figures came in at $113.8 million (Q2 2026), $117.0 million (Q1 2026), and $126.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113.79 Mn |
| Mar 31, 2026 | 116.96 Mn |
| Dec 31, 2025 | 125.98 Mn |
| Sep 30, 2025 | 98.56 Mn |
| Jun 30, 2025 | 104.36 Mn |
| Mar 31, 2025 | 107.22 Mn |
| Dec 31, 2024 | 116.86 Mn |
| Dec 31, 2023 | 10.10 Mn |
| Sep 30, 2015 | 9.41 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Dec 31, 2014 | 31.67 Mn |
| Sep 30, 2010 | 8.57 Mn |
| Jun 30, 2010 | 8.67 Mn |
| Dec 31, 2009 | 8.56 Mn |